Adam C Palmer
@ac_palmer
Followers
789
Following
2K
Media
88
Statuses
753
Assistant Professor, Pharmacology and Computational Medicine at @UNC Measuring and modeling combination cancer therapy
Chapel Hill, NC
Joined May 2012
New paper by @AmyEPomeroy!. A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma. Out now in Blood Cancer Discovery @BCD_AACR. #mathonc #lymsm #BloodCancer.1/n.
7
8
30
RT @GreenLymphoLab: Save-the-date: AACR/ICML Advances In Malignant Lymphoma, June 24-27, 2026, Philadelphia. Featuring interactive sessions….
0
2
0
RT @VincentRK: What I have been worried about. We now spend more on health care than groceries or housing. And it’s not going to slow do….
0
6
0
RT @zakkohane: Atul Butte in memoriam @UCSF @StanfordMed @Harvard @BostonChildrens @BrownUniversity.
0
23
0
RT @Dr_Daniel_Molin: The big debate 3: Smith vs Nowakowski: Is Pola-R-CHP the new standard for all DLBCL? No.
0
5
0
RT @FasaAgbedia: Pola-R-CHP the new SOC for ALL DLBCL?. @SoniSmithMD YES vs. @GregNowakowski NO. Pola-R-CHP, RCHOP.Some need Pola-R-CHP.Som….
0
2
0
Two great resources on the latest in lymphoma:. 1) MD Academy has free recordings of 2025 CLL+Lymphoma meeting. 2) Blood Cancer Discovery has a free collection of lymphoma articles, including a review on ctDNA applications. #lymsm.
4
0
2
RT @StephenVLiu: This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infus….
0
489
0
Clear and compelling interview with @baym on the harm of cutting funding to antibiotic research:. This affects so much of modern medicine; many cancer treatments, including regimens with curative intent, are only safe because of effective antibiotics.
0
15
24
RT @baym: Yesterday, the NIH R35 “Outstanding Investigator” grant to fund scientists in my lab studying antibiotic resistance was terminate….
0
223
0
RT @IBozic_: Thank you @ac_palmer for speaking in the MCMC seminar! The seminar recording is available here:
0
3
0
RT @IBozic_: Excited to announce the second Mathematical and Computational Modeling of Cancer (MCMC) Seminar speaker, Adam Palmer from Univ….
0
6
0
Entertaining interview with Louis Staudt about his work on molecular classification of cancers, and combination therapy. I liked his quote in support of ideas that "amuse your fellow biologists" - which might be his way of saying not everyone will like the idea at first
Congratulations to Dr. Louis Staudt, winner of the AACR Award for Outstanding Achievement in Blood Cancer Research. Attend Dr. Staudt's award lecture and read about his career path and scientific achievements in a Q&A article, online now #AACR25.
0
0
4
RT @CancerGrand: 🚨New in @Nature. Mutographs identified mutational signatures caused by the bacterial genotoxin colibactin are enriched in….
0
9
0
RT @BCD_AACR: A Model of Intratumor and Interpatient Heterogeneity Explains Clinical Trials of Curative Combination Therapy for Lymphoma: h….
0
1
0
RT @BCD_AACR: Beyond Trial and Error: A Mathematical Model Wrangles DLBCL Heterogeneity Toward Optimizing Combination Therapy https://t.co/….
0
3
0
13/13.With much gratitude for discussions with @chidley_chris, @AshAlizadeh, Palmer lab members and others, and support from @theNCI , @UNC_Lineberger, @UNC_PHCO, and UNC Computational Medicine Program.
0
1
4
12/n.This model provides quantitative insight into how combination therapy overcomes heterogeneity within and between tumors to cure many patients with Large B-Cell Lymphoma. We hope it is a useful tool to design new curative-intent combinations using clinical data on new drugs.
1
0
1
11/n.Importantly, @AmyEPomeroy had predicted the success of Pola-R-CHP *before* the trial read out, as she reported from the model prototype back in 2021:.
1
0
1
10/n.Looking at ‘RCHOP+X’ trials, we used clinical data on each ‘drug X’ to predict the clinical trial results. Only Pola-R-CHP, and Tucidinostat plus R-CHOP, were expected to succeed, and indeed they did.
1
0
0
9/n.We calibrated the model to reproduce Progression-Free Survival for the CHOP and RCHOP regimens for Diffuse Large B-Cell Lymphoma. Simulated tumor population shrinkage agreed well with observed changes in circulating tumor DNA after the first cycle of RCHOP:
1
0
0